Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a 'first-in-class' drug which inhibits enzymes involved in cell proliferation, death and migration.


Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Louise Hudman

I'm a freelance GP locum in Winchester & Southampton locum chambers, and Pallant Medical Chambers Clinical Guidelines Lead Partner.

Use the NASGP CPD templates to record your reflections.

No Comments Yet.

Leave your comments